Study guide

8.1 Clinical Assessment & Patient History

Board Certified Pharmacotherapy Specialist BCPS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction and Exam Logistics

1.1 About the BCPS Exam & BPS Specialty Board 1.2 Eligibility, Registration, and Pearson VUE Logistics 1.3 Study Strategies & Exam-Taking Skills for BCPS

2 Chapter 2: Therapeutics: Cardiovascular & Pulmonary

2.1 Cardiovascular Pharmacotherapy 2.2 Pulmonology & Respiratory Care 2.3 Critical Care & Emergency Medicine

3 Chapter 3: Therapeutics: Infectious Diseases

3.1 Infectious Diseases: Antimicrobial Stewardship & Pharmacokinetics 3.2 Infectious Diseases: Common & Severe Infections 3.3 Infectious Diseases: Specialty Infections

4 Chapter 4: Therapeutics: Renal, Endocrine & Gastrointestinal

4.1 Nephrology & Renal Pharmacotherapy 4.2 Endocrinology & Diabetes Mellitus 4.3 Gastroenterology & Hepatic Disorders

5 Chapter 5: Therapeutics: Neurology, Psychiatry & Pain Management

5.1 Pain Management & Palliative Care 5.2 Neurologic Pharmacotherapy 5.3 Psychiatric Pharmacotherapy

6 Chapter 6: Therapeutics: Special Populations

6.1 Geriatric Pharmacotherapy & Beers Criteria 6.2 Pediatric & Neonatal Pharmacotherapy 6.3 Women's Health

7 Chapter 7: Therapeutics: Oncology, Nutrition & Immunology

7.1 Oncology & Support Care 7.2 Nutrition Support 7.3 Immunology, Allergy, & Vaccine-Preventable Diseases 7.4 Urologic Disorders: BPH, Overactive Bladder, and Erectile Dysfunction

8 Chapter 8: Patient Care: Therapeutics & Patient Management

8.1 Clinical Assessment & Patient History 8.2 Clinical Pharmacokinetics: Dosing, Clearance, Vd, and TDM 8.3 Therapeutic Implementation & Medication Reconciliation 8.4 Social Determinants of Health in Treatment Planning

9 Chapter 9: Patient Care: Treatment Monitoring & Outcomes

9.1 Patient Counseling, Education, & Adherence 9.2 Treatment Monitoring: Efficacy, Targets, & Lab Interpretation 9.3 Adverse Drug Event (ADE) Detection & Management

10 Chapter 10: Professional Practice & Evidence-Based Medicine

10.1 Research Methodology & Biostatistics 10.2 Drug Literature Evaluation & Evidence-Based Application 10.3 Medication Safety, Quality of Care, & Public Health

11 Chapter 11: Professional Practice: Systems & Management

11.1 Healthcare Regulations, Standards of Care, & Collaborative Practice 11.2 Pharmacoeconomics, Cost-Benefit Analysis, & Formulary Management

8.1 Clinical Assessment & Patient History

Key Takeaways Explain This Topic AI

A comprehensive clinical assessment integrates subjective and objective data to formulate a pharmacotherapy plan.

Review of Systems (ROS) provides a structured head-to-toe evaluation vital for identifying adverse drug events and untreated indications.

The Beers Criteria is essential for identifying potentially inappropriate medications in older adults.

Medication history must include OTCs, supplements, adherence barriers, and previous adverse drug reactions.

Last updated: July 2026

Clinical Assessment and the Pharmacists' Patient Care Process

The Pharmacists' Patient Care Process (PPCP) provides a consistent framework for delivering patient care: Collect, Assess, Plan, Implement, and Follow-up: Monitor and Evaluate. The foundation of this process lies in the initial clinical assessment and patient history. This requires a systematic approach to gathering subjective and objective information to fully understand the patient's clinical status and medication-related needs.

Subjective vs. Objective Evaluation

Clinical data is traditionally divided into subjective and objective components, forming the basis of the SOAP note format.

Subjective Data: Information provided by the patient, family members, or caregivers. It cannot be directly measured or independently verified by the clinician.

Chief Complaint (CC): The primary reason for seeking care, typically recorded in the patient's own words.

History of Present Illness (HPI): A chronological description of the progression of the patient's present illness. The PQRST mnemonic is frequently used for pain or symptom assessment:

  • P rovocative/Palliative factors
  • Q uality (e.g., sharp, dull, burning)
  • R egion/Radiation
  • S everity (scale 1-10)
  • T emporal characteristics (onset, duration, frequency)
  • Past Medical History (PMH) and Surgical History

Social History (SH): Tobacco use (quantified in pack-years), alcohol intake, illicit drug use, occupation, diet, exercise, and living situation.

Family History (FH): First-degree relatives' medical conditions (e.g., premature cardiovascular disease, diabetes, malignancies) to assess genetic risk.

Review of Systems (ROS): A systematic inquiry to identify symptoms not related to the primary problem.

Objective Data: Information observed or measured by the clinician or obtained through diagnostic testing.

Vital Signs: Blood pressure, heart rate, respiratory rate, temperature, oxygen saturation, and pain score (sometimes considered subjective, but often tracked with vitals).

Physical Examination Findings: Objective signs elicited through inspection, palpation, percussion, and auscultation.

Laboratory Results: Comprehensive metabolic panel (CMP), complete blood count (CBC), lipid panel, thyroid function, etc.

Diagnostic Tests: Electrocardiogram (ECG), chest X-ray (CXR), echocardiogram, imaging studies.

The Physical Examination in Pharmacotherapy

While pharmacists do not perform comprehensive physical exams, targeted physical assessments are increasingly important for evaluating drug efficacy and toxicity.

System Key Findings & Medication Implications

Cardiovascular Edema: Sign of heart failure exacerbation, or adverse effect of dihydropyridine calcium channel blockers (e.g., amlodipine) or TZDs.; Bradycardia: Beta-blocker, non-DHP CCB, or digoxin toxicity.; Irregular Rhythm: Possible atrial fibrillation requiring anticoagulation; QT prolongation from antiarrhythmics or antipsychotics.

Pulmonary Wheezing: Uncontrolled asthma/COPD; possible beta-blocker induced bronchospasm.; Crackles/Rales: Fluid overload in heart failure or pulmonary edema.

Gastrointestinal Abdominal pain: NSAID-induced ulcer, pancreatitis (hypertriglyceridemia, certain HIV meds).; Constipation: Opioid use, anticholinergic burden.

Neurological Tremor: Lithium toxicity, valproic acid side effect, or hyperthyroidism (possibly amiodarone-induced).; Altered Mental Status (AMS): Anticholinergic toxicity, benzodiazepine accumulation, opioid overdose, or systemic infection in older adults.

Dermatological Rash: Drug hypersensitivity (e.g., maculopapular rash from penicillins, Stevens-Johnson Syndrome from lamotrigine, allopurinol, or sulfonamides).; Petechiae/Bruising: Excessive anticoagulation or thrombocytopenia (e.g., heparin-induced thrombocytopenia).

Medication History and Reconciliation

A comprehensive medication history is far more than a list of active prescriptions. It is a critical investigative process.

Prescription Medications: Include drug name, dose, route, frequency, and indication. Verify adherence (e.g., "How many times in the last week have you missed a dose?").

Over-the-Counter (OTC) Medications: Specifically ask about NSAIDs (risk of GI bleed, AKI, hypertension), antihistamines (anticholinergic effects), and antacids/PPIs (drug interactions, e.g., decreasing absorption of iron or itraconazole).

Dietary Supplements and Herbal Products: Often omitted by patients. Identify potential interactions (e.g., St. John's Wort is a potent CYP3A4 inducer and decreases levels of oral contraceptives and statins; Ginkgo biloba increases bleeding risk).

Previous Adverse Drug Reactions (ADRs) and Allergies: Differentiate between true IgE-mediated anaphylactic allergies (hives, wheezing, angioedema) and intolerances or side effects (e.g., GI upset from codeine). This directly impacts future prescribing options.

Geriatric Assessment and the Beers Criteria

Clinical assessment in older adults (≥ 65 years) requires specific considerations due to altered pharmacokinetics, pharmacodynamics, and increased vulnerability to adverse effects. The American Geriatrics Society (AGS) Beers Criteria is a critical tool for identifying potentially inappropriate medications (PIMs).

Key Beers Criteria categories include:

Medications to avoid in most older adults: First-generation antihistamines (highly anticholinergic, risk of confusion and falls); long-acting benzodiazepines (e.g., diazepam, flurazepam) due to prolonged half-life and fall risk; skeletal muscle relaxants (e.g., cyclobenzaprine, carisoprodol).

Medications to avoid in older adults with specific diseases/syndromes: NSAIDs in heart failure (promote fluid retention); anticholinergics in dementia (exacerbate cognitive decline).

Medications to use with caution: Aspirin for primary prevention in adults ≥70 years (increased bleeding risk); dabigatran in patients ≥75 years (higher risk of GI bleeding compared to warfarin and other DOACs).

Drug-drug interactions to avoid: Concomitant use of multiple CNS-active drugs (e.g., opioids + benzodiazepines + gabapentinoids) significantly increases the risk of falls, cognitive impairment, and respiratory depression.

During assessment, the pharmacist must proactively identify "prescribing cascades," where a new medication is prescribed to treat an unrecognised adverse effect of another medication (e.g., prescribing a Parkinson's disease medication like benztropine to treat extrapyramidal symptoms caused by metoclopramide, rather than simply discontinuing the offending metoclopramide).